Treatment with aspirin for recurrent abortion

Treatment with acetylsalicylic acid for idiopathic recurrent abortion: a randomised trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN88763155

Enrollment

400

Registered

2009-11-12

Start date

2008-01-01

Completion date

Unknown

Last updated

2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic recurrent abortion Pregnancy and Childbirth Spontaneous abortion

Interventions

ASA 75 mg, taken orally, given between gestational weeks 6 - 36. Controls are given placebo pills. Follow-up is until the pregnancy has ended, either as a miscarriage or as a delivery. Follow-up will

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Female participants aged 18 - 38 years 2. Idiopathic recurrent abortion, defined as at least three miscarriages between gestational weeks 6 - 12 within the same relationship. One full term pregnancy can be included. 3. Work-up according to the study protocol without a positive finding

Exclusion criteria

Exclusion criteria: 1. Allergy to ASA 2. Previous participation in the study 3. Age above 37 years 4. Body mass index (BMI) above 35 kg/m^2 5. Positive findings in the work-up, requiring specific treatment for recurrent abortion 6. Concurrent treatment with ASA for other condition

Design outcomes

Primary

Measure	Time frame
Live birth at at least 24 gestational weeks	—

Secondary

Measure	Time frame
1. Miscarriage, recorded when they occur, as patients report or at specified controls at gestational weeks 9, 12, 20, 30 and 36 2. Vaginal bleeding, recorded when they occur, as patients report or at specified controls at gestational weeks 9, 12, 20, 30 and 36 3. Placenta praevia, recorded when they occur, as patients report or at specified controls at gestational weeks 9, 12, 20, 30 and 36 4. Premature delivery, measured in hospital at or after delivery 5. Intrauterine growth retardation, measured until discharge from hospital after delivery 6. Pre-eclampsia, recorded when they occur, as patients report or at specified controls at gestational weeks 9, 12, 20, 30 and 36 7. Perinatal mortality, measured until discharge from hospital after delivery 8. Perinatal morbidity, measured as Apgar score and days in neonatal intensive care unit, measured until discharge from hospital after delivery	—

Measure

Time frame

1. Miscarriage, recorded when they occur, as patients report or at specified controls at gestational weeks 9, 12, 20, 30 and 36 2. Vaginal bleeding, recorded when they occur, as patients report or at specified controls at gestational weeks 9, 12, 20, 30 and 36 3. Placenta praevia, recorded when they occur, as patients report or at specified controls at gestational weeks 9, 12, 20, 30 and 36 4. Premature delivery, measured in hospital at or after delivery 5. Intrauterine growth retardation, measured until discharge from hospital after delivery 6. Pre-eclampsia, recorded when they occur, as patients report or at specified controls at gestational weeks 9, 12, 20, 30 and 36 7. Perinatal mortality, measured until discharge from hospital after delivery 8. Perinatal morbidity, measured as Apgar score and days in neonatal intensive care unit, measured until discharge from hospital after delivery

—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026